Dialog Box

Cachexia in NSCLC


A phase 3 Randomised, Double-Blind, Placebo-Controlled, Multicentre Study to Evaluate the Efficacy and safety of Anamorelin HCL for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced non-small cell lung cancer (NSCLC)

Research Overview

Weight loss and anorexia are among the symptoms that characterize cancer cachexia, occurring in more that 80% of patients with cancer before death. The aim of this study is to demonstrate superiority of anamorelin against placebo on the gain of body weight and improvement in anorexia symptoms and to evaluate the safety and tolerability of anamorelin amongst this group of patients

Key Contact

Name: Centre for Palliative Care

Email: svhm.CPCtrials@svha.org.au

Project Team:

  • Principal Investigator - Associate Professor Jennifer Weil
  • Associate Investigator – Dr Melissa Moore
  • Research Nurses – Indy Khera, Di Saward

Funding Source

Helsinn Healthcare SA - Switzerland

20 November 2019
Category: Current Projects - Clinical Trials